BNOX Bionomics
- 0.731
- +0.001+0.15%
- 0.685
- -0.046-6.29%
Bionomics News
Bionomics | 6-K: Report of foreign private issuer (related to financial reporting)
Bionomics BNOX Private Placement; Adaptimmune ADAP Galapagos Collaboration
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNovo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday's pre-market session. The company's market cap stands at $14.5 million. Adaptimmune Therapeutics (NASD
Express News | Bionomics Shares Are Trading Higher After the Company Announced a Private Placement of up to $70 Million
Express News | Bionomics Limited Private Placement Of ADSs With Institutional Investor For Total Gross Proceeds Of Up To $70M
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 84.3% to $2.34 during Tuesday's regular session. The market value of their outstanding shares is at $10.2 million. Genelux (NASDAQ:GNLX)
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersOneMedNet (NASDAQ:ONMD) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. Aesthetic Medical Intl (N
Buy Rating Affirmed for Bionomics' BNC210 Following Promising PTSD Study Results
Bionomics's BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis
Bionomics Reveals Detailed Data From PTSD Trial, Stock Soars
Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post-traumatic stress disorder (PTSD).In September 2023, Bionomics
Express News | Bionomics Shares Are Trading Higher After the Company Disclosed Results of Phase 2b ATTUNE Trial of BNC210 in Post-traumatic Stress Disorder
Express News | Bionomics Disclosed Results Of The Full Dataset Analysis From ATTUNE Phase 2b Trial Of BNC210 In Patients With Post-Traumatic Stress Disorder
Bionomics Reports Results of the Full Dataset Analysis From ATTUNE Phase 2b Trial of BNC210 in Patients With Post-Traumatic Stress Disorder
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.
Global Post-traumatic Stress Disorder (PTSD) Drug Pipeline Landscape Report 2024 Featuring Tonix Pharmaceuticals, Pop Test Oncology, H. Lundbeck, Bionomics, and Alto Neuroscience
Bionomics to Present at the 2024 BIO CEO & Investor Conference
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric
Ocugen, Community Health Systems Among Healthcare Movers
Bionomics: A Strong Buy on Clinical and Regulatory Milestones
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data
US stocks look set to open the week on a positive note, rising higher in Monday's premarket session higher ahead of the index of leading economic indicators for December that is to be released later i
XPEV, BILI and ROMA Among Pre-market Losers
Analysis
Price Target
No Data
